Viridian Therapeutics Inc (NASDAQ:VRDN) shares, rose in value on Wednesday, March 26, with the stock price down by -4.32% to the previous day’s close as strong demand from buyers drove the stock to $14.16.
Actively observing the price movement in the last trading, the stock closed the session at $14.80, falling within a range of $14.03 and $14.8099. The value of beta (5-year monthly) was 1.088. Referring to stock’s 52-week performance, its high was $27.20, and the low was $11.40. On the whole, VRDN has fluctuated by -8.88% over the past month.
With the market capitalization of Viridian Therapeutics Inc currently standing at about $1.15 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 44.08k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VRDN’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of VRDN currently trading nearly -8.41% and -16.05% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 34.32, while the 7-day volatility ratio is showing 4.24% which for the 30-day chart, stands at 5.40%. Furthermore, Viridian Therapeutics Inc (VRDN)’s beta value is 0.81, and its average true range (ATR) is 0.80.
A comparison of Viridian Therapeutics Inc (VRDN) with its peers suggests the former has fared considerably weaker in the market. VRDN showed an intraday change of -4.32% in last session, and over the past year, it shrunk by -21.38%%.
Data on historical trading for Viridian Therapeutics Inc (NASDAQ:VRDN) indicates that the trading volumes over the past 10 days have averaged 0.7 and over the past 3 months, they’ve averaged 1.01 million. According to company’s latest data on outstanding shares, there are 80.99 million shares outstanding.
Nearly 10.07% of Viridian Therapeutics Inc’s shares belong to company insiders and institutional investors own 102.34% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.0 million shares as on 2025-03-14, resulting in a short ratio of 11.4. According to the data, the short interest in Viridian Therapeutics Inc (VRDN) stood at 1388.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 9.74 million. The stock has fallen by -26.13% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VRDN stock heading into the next quarter.
